newsfilter
← Latest News
GlobeNewswire·

TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors,